Rossmax International Ltd (4121) Fair Value & Analysis
Healthcare · TW · Market cap 1.1B TWD
Fair value as of: Jul 21, 2026
From 11 valuation models · updated 20 days ago
Share price −1.5% over the past month.
A solid business, screening 165% undervalued on our models.
What matters now
- The price is below even our cautious bear case (23.33 TWD). The market is more pessimistic than our downside scenario.
- Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (23.33 TWD to 46.17 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 11.65 TWD – 34.59 TWD · fair‑value band 23.33 TWD – 46.17 TWD · the 13.10 TWD price screens below the 34.75 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Rossmax International Ltd (4121) currently trades at 13.10 TWD, while our model-based Fair Value estimate is 34.75 TWD, implying the stock looks roughly 165.3% undervalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Rossmax International Ltd generated revenue of 3.8B TWD at a net margin of -0.8%. Revenue grew 1.4% year over year. It earns a return on equity of -3.3%. Net debt stands at 905M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 23.33 TWD (bear case) to 46.17 TWD (bull case); at 13.10 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 165%, 4121 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 11 models by family
Widest divergence: Multiples (42.35 TWD) versus Asset-Based (11.42 TWD). Highest evidence: Growth DCF (80).
Notify me when 4121 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 41
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Rossmax International Ltd. develops and supplies healthcare products and solutions. The company offers body fat monitors and scales that are used to measure body fat, body mass index, lean mass, muscle mass, and water ratio along with body weight; blood pressure monitors; sphygmomanometer, a device that measures blood pressure; stethoscope, an acoustic …
Full company description
Rossmax International Ltd. develops and supplies healthcare products and solutions. The company offers body fat monitors and scales that are used to measure body fat, body mass index, lean mass, muscle mass, and water ratio along with body weight; blood pressure monitors; sphygmomanometer, a device that measures blood pressure; stethoscope, an acoustic medical device for auscultation, or listening to the internal sounds of an animal or human body; handheld pulse oximeter monitors to measure the amount of oxygen carried in the body; non-contact telephoto thermometers used to measure human body temperature; and blood glucose monitoring system, a medical device for determining the approximate concentration of glucose in the blood. It also provides nebulizer, a drug delivery device used to administer medication in the form of a mist; suction unit, a machine used to remove mucus and other bodily fluids; aero spacer, a device used to increase the ease of administering aerosolized medication; peak flow meter, a device used to monitor a person's ability to breathe out air; heating pads used for therapy; and anti-decubitus mattresses. In addition, the company operates Rossmax healthstyle app, which allows customers to monitor blood pressure, blood glucose, SpO2, weight, and temperature through a single app. It provides healthcare products in the fields of cardiovascular, diabetes, respiratory, fever, and wound healing diseases, as well as thermometers, scales, and nebulizers for kidshealth. The company also exports its products. It operates in Taiwan, America, Europe, East Asia, South Asia, India, Middle East, Africa, and internationally. Rossmax International Ltd. was founded in 1988 and is based in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Rossmax International Ltd reported revenue of 3.8B TWD in FY2025 versus 3.9B TWD in FY2021, a compound −1.0%/yr. Reported net income was −29.9M TWD in FY2025.
Watch 4121: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Rossmax International Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Rossmax International Ltd (4121) overvalued or undervalued?
What is the fair value of 4121?
What is the quality score of 4121?
What is the revenue of Rossmax International Ltd (4121)?
What is the net profit margin of 4121?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Rossmax International Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.